June 12, 2020 04:46 PM EDT
R&D

UCB flash­es the da­ta be­hind its pos­i­tive pso­ri­a­sis read­outs. Can it com­pete in a crowd­ed field?

Jason Mast

Editor

Eight months af­ter UCB an­nounced that a lit­tle-watched drug can­di­date out­per­formed J&J’s block­buster Ste­lara, the Bel­gian phar­ma is out with full da­ta that one …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times